Ep. 255, Chapter 5: Global Dollars And Sense with Yaniv Sneor

44:40 – End

Sneor clarifies that Mid Atlantic Bio Angels is agnostic to company location, investing across the US and internationally. While European and Asian syndicate partners often seek MAB Angels' investment in their opportunities, they are less inclined to invest in MAB Angels' portfolio companies — a disparity Sneor suggests stems from differences in startup environments, talent, and tolerance for failure across continents. Sneor also discusses his work as CEO of Native State Therapeutics, an early-stage company targeting protein misfolding neurodegenerative diseases like Parkinson's and Alzheimer's. He concludes by commenting upon the shakeup at NIH and FDA, which could influence pharma's R&D focus and ultimately affect MAB Angels' long-term investment strategies.